AP NEWS
Press release content from ACCESSWIRE. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from ACCESSWIRE
Press release content from ACCESSWIRE. The AP news staff was not involved in its creation.

Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live “HIV Community Conversation” Event with Transgender Advocate Yonce Jones November 22, 2019 at 3 p.m. Eastern

November 21, 2019
SAN FRANCISCO, CA / ACCESSWIRE / November 21, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), is hosting a Facebook Live conversation ...
SAN FRANCISCO, CA / ACCESSWIRE / November 21, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), is hosting a Facebook Live conversation ...

SAN FRANCISCO, CA / ACCESSWIRE / November 21, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), today announced that the Company’s wholly-owned subsidiary, Napo Pharmaceuticals, Inc. (“Napo”), is hosting a Facebook Live conversation at 3 p.m. Eastern tomorrow, November 22, 2019, between Josh Robbins and Yonce Jones, a prominent HIV/transgender advocate. The discussion is part of Napo’s monthly “HIV Community Conversations” series and can be viewed on Napo’s Facebook page: facebook.com/napopharma.

The upcoming discussion, titled Stigma: HIV & Transgender, is the fifth event in the HIV Community Conversations series, which brings key advocates and activists in the HIV community together to talk about issues that matter most to people living with and affected by HIV/AIDS.

“This conversation with Yonce Jones will highlight her experience living with HIV as a transgender woman as she bravely opens up about the stigma she and others continue to face,” Robbins commented. “It is an honor to have such a diverse group of perspectives in these HIV Community Conversations each month and it showcases Napo’s commitment toward those of us living with the virus.”

Tomorrow’s discussion is the final HIV Community Conversation prior to the inaugural “HIV Activism Digital Summit,” which is scheduled to take place Friday, December 13, 2019 on Napo’s social media channels. Presented by Napo, this summit will be the first completely digital, activist-led virtual program in the HIV community and is intended to continue fostering the important conversations needed to address living with HIV and living with comorbidities like HIV-associated diarrhea.

Jones, a transgender woman living with HIV, serves as a Peer Empowerment Leader with Harlem United, an organization in New York City funded by AIDS United’s Positive Organizing Project. For nearly three decades, Harlem United has changed lives by helping marginalized communities improve their health and well-being through compassionate, client-centered care.

Robbins is an HIV activist, blogger, writer, social media marketer, and a consultant to Napo. He was recently honored with the National Lesbian & Gay Journalist Association “Excellence in Journalism: Blogging Award”. He is a GLAAD-nominated blogger, a keynote and university speaker on sexual health and overcoming difficulty to live well, and he gave a TEDx Talk on how patients use social media to maintain healthy lifestyles despite chronic conditions.

About Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.

About Mytesi®

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the expectation that Napo will host a Facebook Live “HIV Community Conversation” event November 22, 2019, and the expectation that Napo will host an HIV Activism Digital Summit Friday, December 13, 2019. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Some of the factors that could affect our actual results are included in the periodic reports on Form 10-K and Form 10-Q that we file with the Securities and Exchange Commission. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

Peter Hodge

Jaguar Health, Inc.

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View source version on accesswire.com: